Pivotal bioVenture Partners Investment Advisor LLC
In its 13F for Q4 2025 (holdings as of December 31, 2025, filed February 13, 2026), Pivotal bioVenture Partners Investment Advisor LLC reported 12 stock positions worth $258.7 million. Its top holding was Vaxcyte (PCVX) at 24.5% of the portfolio, followed by Oculis (OCS, 17.7%) and Arcutis Biotherapeutics (ARQT, 15.3%). Compared with Q3 2025, it opened 2 new positions, added to 1 and reduced 3. The biggest buy was a new position in Evommune (EVMN) and the biggest sale Arcutis Biotherapeutics (ARQT, shares −36%).
- Most Recent 13F
- Q2 2026
- Location
- SAN FRANCISCO, CA
- CIK
- 0001844645
- Portfolio Value
- $258.7M (Q4 2025)
- SEC Filing
- 0001012975-26-000133 ↗ filed Feb 13, 2026
Holdings Value
Holdings 12 stocks · $258.7M
| PCVX Vaxcyte Inc. | 24.48% | 1,372,425 | $63.3M | No change |
| OCS Oculis Holding AG | 17.67% | 2,288,658 | $45.7M | Reduce -0.5% |
| ARQT Arcutis Biotherapeutics Inc. | 15.34% | 1,366,624 | $39.7M | Reduce -35.5% |
| EVMN Evommune Inc. | 12.75% | 1,926,943 | $33.0M | New |
| ZBIO Zenas Biopharma Inc. | 8.31% | 591,991 | $21.5M | Reduce -24.0% |
| TRVI Trevi Therapeutics Inc. | 6.08% | 1,256,782 | $15.7M | No change |
| IMNM Immunome Inc. | 6.08% | 732,512 | $15.7M | Add +45.8% |
| MPLT Maplight Therapeutics Inc. | 4.15% | 611,447 | $10.7M | New |
| BIOA Bioage Labs Inc. | 3.34% | 653,374 | $8.6M | No change |
| RXRX Recursion Pharmaceuticals-A | 0.94% | 595,518 | $2.4M | No change |
| RLYB Rallybio Corp. | 0.64% | 2,404,644 | $1.6M | No change |
| BOLT Bolt Biotherapeutics Inc. | 0.20% | 94,573 | $517K | No change |
Portfolio Sells Q3 2025 → Q4 2025
Portfolio Buys Q3 2025 → Q4 2025
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 13 | $307.8M | PCVX, ARQT, TRVI, AVLN, EVMN |
| Q1 2026 | 13 | $279.8M | PCVX, OCS, EVMN, ARQT, TRVI |
| Q4 2025 | 12 | $258.7M | PCVX, OCS, ARQT, EVMN, ZBIO |
| Q3 2025 | 10 | $173.0M | PCVX, OCS, ARQT, ZBIO, TRVI |
| Q2 2025 | 12 | $161.3M | OCS, PCVX, ARQT, INZY, ZBIO |
| Q1 2025 | 11 | $123.6M | OCS, ARQT, PCVX, ZBIO, INZY |
| Q4 2024 | 11 | $148.1M | PCVX, OCS, ARQT, INZY, ZBIO |
| Q3 2024 | 11 | $168.5M | PCVX, INZY, ARQT, OCS, ZBIO |
| Q2 2024 | 10 | $130.1M | PCVX, INZY, OCS, ARQT, EXAI |
| Q1 2024 | 11 | $155.6M | PCVX, INZY, ARQT, OCS, FUSN |